Medicus Pharma (MDCX) Income from Non-Controlling Interests (2025)
Medicus Pharma (MDCX) reported Income from Non-Controlling Interests of -$69.0 for Q4 2025, down 192.0% quarter-over-quarter from $75.0 in Q3 2025.
Medicus Pharma (MDCX) Income from Non-Controlling Interests (2025) Analysis & Trends
Medicus Pharma has reported Income from Non-Controlling Interests for 1 years, with the latest figure at -$69.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Non-Controlling Interests changed N/A year-over-year to -$69.0; the trailing twelve-month figure through Dec 2025 stood at $6.0 (changed N/A YoY), and the FY2025 full-year result was -$146.0, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q4 2025 stood at -$69.0, down from $75.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $75.0 in Q3 2025, with the low at -$69.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Medicus Pharma | 6.05 Mn | 6.15 Mn | - | -69.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -69.00 |
| Sep 30, 2025 | 75.00 |